Using 68Ga-Pentixafor PET/CT to improve diagnosis and treatment of primary aldosteronism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of 68Ga-Pentixafor PET/CT imaging to enhance the diagnosis and treatment strategies for primary aldosteronism, a common cause of secondary hypertension. It aims to provide a non-invasive alternative to adrenal vein sampling (AVS), which has a success rate of only 80%. The study will evaluate changes in adrenal tissue structure and function before and after superselective adrenal artery embolization (SAAE) using this imaging technique. By improving diagnostic accuracy, the study seeks to facilitate better management of patients with primary aldosteronism.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult population (aged 18 years or order);
* patients with suspected or new diagnosed Primary aldosteronism (supporting evidence may include MRI, CT, laboratory tests);
* patients who had scheduled 68Ga-BNU-PSMA PET/CT scan;
* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee;
* healthy volunteers(aged 18 years or order).

Exclusion Criteria:

* patients with pregnancy;
* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Weibing Miao, MD
• Email: miaoweibing@126.com
• Phone: 86-0591-87981618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

• FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer

  This study will try 18F‑FAPI‑74 PET/CT scans in adults with suspected or recurrent pancreatic cancer to see if they detect lymph node spread and distant metastases more accurately.

  Recruiting Phase 2/3 Turku University Hospital · Turku · NCT07098598

• Establishing a cohort for Alzheimer's disease research in China

  This study is trying to understand how brain scans and other health markers relate to Alzheimer's disease in both people with and without cognitive issues in China, to help find ways to detect and prevent the disease early.

  Recruiting Huashan Hospital · Shanghai · NCT06827678

• Using PET/CT imaging to diagnose GLP-1 receptor related diseases

  This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06725693

• Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients

  This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690970

• Evaluating PET/CT for SSTR-related diseases

  This study is testing a new type of PET/CT scan to see if it can help find cancer spots in adults who have tumors related to SSTR diseases.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.